In this letter to the editor, we present results of claims data analysis. This claims
data analysis supports a hypothesis that in patients with hereditary angioedema due
to C1-esterase inhibitor (C1-INH) deficiency, the occurrence and/or symptomatology
of coexisting autoimmune disease may be positively influenced by a replacement therapy
with plasma derived C1-INH.